Showing results (71-80 of 163) with videos related to

Sort By:
Pageof 17
Cancer|September 22, 2007
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemiaMonica Else, Nnenna Osuji, Francesco Forconi, et al.
Blood|May 16, 2002
Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemiaMartin Yuille, Alison Condie, Chantelle Hudson, et al.
Blood|September 28, 2011
Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous routeClaire E Dearden, Amit Khot, Monica Else, et al.
Leukemia & Lymphoma|December 11, 2007
Birth order pattern in the inheritance of chronic lymphocytic leukaemia and related lymphoproliferative diseaseViggo Jønsson, Geir Tjønnfjord, Sven Ove Samuelsen, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|March 30, 2004
CD38 expression as a prognostic indicator in chronic lymphocytic leukaemiaPatrick D Thornton, Cristina Fernandez, Giada M Giustolisi, et al.
Cureus|March 20, 2020
Lactobacillus rhamnosus Bacteremia in an Immunocompromised Renal Transplant PatientSelin Sendil, Isha Shrimanker, Qurat Mansoora, et al.
British Journal of Haematology|February 6, 2016
The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with <97% identity and similar to those with 98% identityZadie Davis, Francesco Forconi, Anton Parker, et al.
British Journal of Haematology|September 29, 2012
Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphomaMonica Else, Ana Marín-Niebla, Fátima de la Cruz, et al.
Blood|July 2, 2002
ATM mutations are rare in familial chronic lymphocytic leukemiaMartin R Yuille, Alison Condie, Chantelle D Hudson, et al.
Cancer|October 26, 2005
Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 yearsMonica Else, Rosa Ruchlemer, Nnenna Osuji, et al.
Pageof 17